You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

BIMATOPROST Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


DrugPatentWatch® Litigation and Generic Entry Outlook for Bimatoprost

A generic version of BIMATOPROST was approved as bimatoprost by APOTEX on December 1st, 2014.

  Try a Trial

Drug patent expirations by year for BIMATOPROST
Drug Prices for BIMATOPROST

See drug prices for BIMATOPROST

Drug Sales Revenue Trends for BIMATOPROST

See drug sales revenues for BIMATOPROST

Recent Clinical Trials for BIMATOPROST

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Laboratoires TheaPhase 1
Amneal Pharmaceuticals, LLCPhase 3
Medical University of South CarolinaEarly Phase 1

See all BIMATOPROST clinical trials

Pharmacology for BIMATOPROST
Medical Subject Heading (MeSH) Categories for BIMATOPROST
Anatomical Therapeutic Chemical (ATC) Classes for BIMATOPROST
Paragraph IV (Patent) Challenges for BIMATOPROST
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
LUMIGAN Ophthalmic Solution bimatoprost 0.01% 022184 1 2011-04-05
LATISSE Topical Solution bimatoprost 0.03% 022369 1 2010-05-03
LUMIGAN Ophthalmic Solution bimatoprost 0.03% 021275 1 2008-12-22

US Patents and Regulatory Information for BIMATOPROST

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alembic BIMATOPROST bimatoprost SOLUTION/DROPS;OPHTHALMIC 210263-001 Apr 12, 2019 AT RX No Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Micro Labs BIMATOPROST bimatoprost SOLUTION/DROPS;OPHTHALMIC 202505-001 Sep 8, 2020 AT RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Gland Pharma Ltd BIMATOPROST bimatoprost SOLUTION/DROPS;OPHTHALMIC 210126-001 Mar 22, 2019 AT RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Hikma BIMATOPROST bimatoprost SOLUTION/DROPS;TOPICAL 203051-001 Oct 9, 2018 AT RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Sandoz BIMATOPROST bimatoprost SOLUTION/DROPS;OPHTHALMIC 202565-001 May 5, 2015 AT RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Apotex BIMATOPROST bimatoprost SOLUTION/DROPS;OPHTHALMIC 090449-001 Jul 20, 2015 AT RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for BIMATOPROST

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
AbbVie Deutschland GmbH & Co. KG Lumigan bimatoprost EMEA/H/C/000391
Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).,
Authorised no no no 2002-03-08
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.